Screener
Halozyme Therapeutics HALO EV / EBITDA
EV / EBITDA at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Halozyme Therapeutics’s 10-Q, filed November 3, 2025. Open the filing →
- Filed
- Nov 3, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001159036-25-000045
FAQ
- What is Halozyme Therapeutics's EV / EBITDA?
- Halozyme Therapeutics (HALO) reported EV / EBITDA of 13× in Q3 2025.
- How has Halozyme Therapeutics's EV / EBITDA changed year-over-year?
- Halozyme Therapeutics's EV / EBITDA decreased by 27.0% year-over-year, from 17.8× to 13×.
- What is the long-term trend for Halozyme Therapeutics's EV / EBITDA?
- Over 4 years (2020 to 2024), Halozyme Therapeutics's EV / EBITDA has grown at a -24.8% compound annual growth rate (CAGR), from 41.7× to 13.4×.
- What does EV / EBITDA mean?
- Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.
Ask your AI about Halozyme Therapeutics's ev / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude